As investment fuels brain diagnostics, Amprion’s expansion highlights growing belief that better tests are just as important as better drugs.
The race against neurodegenerative disease has largely focused on finding the next breakthrough drug. However, a growing number of researchers are beginning to ask a different question: what if one of the biggest bottlenecks isn’t the medicine, but knowing exactly who should receive it? That question sits at the heart of two conversations reshaping the field.
The first is about de-risking drug development. Every failed clinical trial represents years of work and billions of dollars, but sometimes a promising therapy isn’t what fails. Sometimes the wrong patients are enrolled because diagnosing diseases like Parkinson’s or Lewy body dementia remains remarkably difficult, particularly in their early stages. Companies like Amprion are increasingly becoming the gateway that helps biopharma identify the right patients before a trial even begins. If that’s true, could expanding diagnostic capacity ultimately help speed the arrival of disease-modifying therapies?
The second conversation is even broader. As medicine shifts toward detecting disease before symptoms become severe, biomarkers – the measurable biological signs that reveal what’s happening inside the body – have become one of healthcare’s hottest currencies. Companies that develop reliable biomarker technologies are no longer simply selling diagnostic tests; they’re helping define how diseases are identified, studied and eventually treated.
Those questions make the announcement from Amprion about far more than another funding round. The San Diego-based diagnostics company has secured a multi-million-dollar growth investment from Decathlon Capital Partners, allowing it to expand its testing capacity for neurodegenerative diseases while maintaining its independence through a financing structure that avoids shareholder dilution and changes to management control [1].
Demand for Amprion’s diagnostic testing has been rising as clinicians and researchers look for more reliable ways to distinguish between disorders such as Parkinson’s disease, Lewy body dementia and certain forms of Alzheimer’s disease. Unlike many neurological conditions that share overlapping symptoms, these diseases leave behind different biological fingerprints. Amprion’s technology looks for those fingerprints using what is known as Seed Amplification Assay (SAA).
Say, trying to determine whether a tiny ember is hidden somewhere in a forest. Instead of searching every tree one by one, you create the conditions that would cause the ember to grow into a visible flame. SAA follows a similar concept. Rather than trying to spot minute amounts of abnormal proteins directly, the test encourages those proteins to multiply in the laboratory until they become much easier to detect. The result is a clearer biological signal that can support diagnosis, particularly when symptoms alone don’t tell the full story.
Amprion says its technology is also used beyond routine diagnosis, supporting research, drug development and commercialization efforts across the neurodegenerative disease landscape.
The investment from Decathlon Capital Partners isn’t just notable because of its size; it also reflects a financing strategy becoming increasingly attractive for growing health technology companies. Rather than raising traditional equity that would dilute ownership or shift decision-making, Amprion secured growth capital while retaining management control.
Russ Lebovitz, the CEO of Amprion, said that global demand for the company’s testing is on the rise due to researchers and clinicians increasingly recognizing the importance of dependable, pathology-based insights into Parkinson’s disease, Lewy body dementia and other related neurodegenerative disorders.
“This investment from Decathlon Capital Partners strengthens our ability to meet that demand and accelerate the global adoption of our seed-amplification testing. The tailored financing package provides the operational flexibility needed to support our growth strategy while remaining non-dilutive to existing shareholders and preserving our management control and governance structure,” he added.
For a company operating in one of healthcare’s fastest-moving areas, maintaining that strategic flexibility could prove as valuable as the capital itself.
Why diagnostics is becoming the new competitive advantage
The longevity sector often celebrates breakthroughs in therapeutics, but diagnostics have become one of the field’s fastest-growing frontiers. After all, precision medicine only works if clinicians know precisely what they’re treating.
In neurological disease, that has long been a problem. Parkinson’s, Lewy body dementia and Alzheimer’s can present with similar symptoms, especially during the early stages when interventions may have the greatest potential. More accurate diagnostic tools help reduce uncertainty – not only for patients and families, but also for researchers designing clinical trials. That matters because modern drug development increasingly depends on selecting the right patients from the start. A trial targeting one specific disease process becomes much more likely to succeed if participants actually have that underlying biology. In other words, diagnostics are evolving from being a supporting service to becoming part of the therapeutic strategy itself.
Amprion’s position extends beyond offering laboratory testing. The company also holds intellectual property surrounding its SAA methodology, placing it at an influential point in an increasingly biomarker-driven ecosystem.
As pharmaceutical companies invest heavily in targeted therapies, demand for dependable biological confirmation is likely to grow alongside them. That doesn’t necessarily make Amprion the sole gatekeeper to future neurological care – science rarely follows a single path, and competing technologies continue to emerge. However, it does position the company as one of the infrastructure players helping shape how future therapies are developed, validated and delivered.
In longevity, infrastructure often receives less attention than breakthrough drugs or futuristic interventions. Yet history repeatedly shows that transformative advances depend on equally transformative tools. Better sequencing accelerated genomics. Better imaging transformed oncology. Better biomarkers could do something similar for brain health.
Whether this new investment directly shortens the timeline to a disease-modifying therapy for Parkinson’s remains impossible to predict. Capital alone doesn’t produce scientific breakthroughs. But by expanding the capacity to identify patients more accurately – and by strengthening one of the technologies increasingly used to match biology with treatment – Amprion is helping remove one of the obstacles that has slowed neurological research for years.
